Literature DB >> 1846838

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

Y R Mahida1, C E Lamming, A Gallagher, A B Hawthorne, C J Hawkey.   

Abstract

Interleukin 1 beta in biopsy specimens from inflamed colonic mucosa of patients with active inflammatory bowel disease was studied. Compared with normal colonic mucosal biopsy specimens, a significantly greater amount of interleukin 1 beta was present in rectal mucosa before (median (range) 4.3 (2.0-11.8) v 119.2 (30.1-286.8) pg/mg; p less than 0.01) and produced during organ culture (39.1 (9.4-106.8) v 97.6 (28.2-991.6) pg/mg; p less than 0.01). Values of interleukin 1 beta after culture correlated with concentrations of thromboxane B2. Organ culture of inflamed biopsy specimens in the presence of 5 aminosalicylic acid and dexamethasone reduced the amount of interleukin 1 beta detected. At the doses studied, 5 aminosalicylic acid also reduced the amount of leukotriene B4 detected after culture.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846838      PMCID: PMC1379213          DOI: 10.1136/gut.32.1.50

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  Prostaglandins as endogenous mediators of interleukin 1 production.

Authors:  S L Kunkel; S W Chensue; S H Phan
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

2.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.

Authors:  Y R Mahida; K Wu; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

Review 3.  Interleukin 1 and the pathogenesis of inflammatory diseases.

Authors:  C P Maury
Journal:  Acta Med Scand       Date:  1986

4.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

5.  Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.

Authors:  Y R Mahida; K C Wu; D P Jewell
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

Review 6.  Biology of interleukin 1.

Authors:  C A Dinarello
Journal:  FASEB J       Date:  1988-02       Impact factor: 5.191

7.  Inhibition of platelet thromboxane synthetase by sulfasalazine.

Authors:  W F Stenson; E Lobos
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

8.  Inhibition of prostaglandin synthetase in human rectal mucosa.

Authors:  C J Hawkey; M Lo Casto
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

9.  Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer.

Authors:  C J Hawkey
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

10.  Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms.

Authors:  J A Kern; R J Lamb; J C Reed; R P Daniele; P C Nowell
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

View more
  41 in total

1.  Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa.

Authors:  Christine Bäuerl; Marta Llopis; María Antolín; Vicente Monedero; Manuel Mata; Manuel Zúñiga; Francisco Guarner; Gaspar Pérez Martínez
Journal:  Genes Nutr       Date:  2012-06-06       Impact factor: 5.523

Review 2.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 3.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 4.  Explant organ culture: a review.

Authors:  J H Resau; K Sakamoto; J R Cottrell; E A Hudson; S J Meltzer
Journal:  Cytotechnology       Date:  1991-11       Impact factor: 2.058

5.  Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease.

Authors:  Doris Meister; Subrata Ghosh
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

Review 6.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

Review 7.  Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.

Authors:  Antonio Tursi; Raymond E Joseph; Paul Streck
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

Review 8.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

9.  Adhesion molecules in inflammatory bowel disease.

Authors:  S C Jones; R E Banks; A Haidar; A J Gearing; I K Hemingway; S H Ibbotson; M F Dixon; A T Axon
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

10.  Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.

Authors:  D Rachmilewitz; F Karmeli; L W Schwartz; P L Simon
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.